Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Year: 2024
Type: article
Abstract: Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
Source: JCO Oncology Practice
DOI: 10.1200/op-24-00626
Authors: Neal Shore, Sarah M. Nielsen, Edward D. Esplin, Emmanuel S. Antonarakis, Pedro C. Barata, Tomasz M. Beer, Himisha Beltran, Alan Bryce, Michael S. Cookson, E. David Crawford, Tanya B. Dorff, Daniel J. George, Elisabeth I. Heath, Brian T. Helfand, Maha Hussain, Rana R. Mckay, Alicia K. Morgans, Michael J. Morris, Channing J. Paller, Ashley E. Ross, Oliver Sartor, John Shen, Paul Sieber, Matthew R. Smith, David R. Wise, Andrew J. Armstrong
Institutions: Carolina Urologic Research Center, Invitae (United States), University of Minnesota, Masonic Cancer Center, Case Western Reserve University, Oregon Health & Science University, Exact Sciences (United States), OHSU Knight Cancer Institute, Dana-Farber Cancer Institute, City of Hope, OU Health Stephenson Cancer Center, University of Oklahoma, University of California San Diego, Duke University, Duke Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Endeavor Health, Northwestern University, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Mayo Clinic, University of California, Los Angeles, Massachusetts General Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Funders: Invitae, National Cancer Institute
OpenAlex ID: W4405595547